Oncologist : Impact Factor & More
eISSN: 1549-490XpISSN: 1083-7159
Open AccessShare this on:
Key Metrics
CiteScore 
8.5
Impact Factor
5 - 10
SNIP
1.61
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Oncologist Journal Specifications
| Overview | |
| Publisher | OXFORD UNIV PRESS |
| Language | English |
| Frequency | Monthly |
| Article Processing Charges | USD 3494 |
| Publication Time | 19 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | Society for Translational Oncology |
| Frequency | Monthly |
| Publication Start Year | 1996 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Oncologist ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Oncologist
Impact of geriatric covariates on metronomic cyclophosphamide efficacy and tolerance-the CHEMETROLD study.
- 13 Apr 2026
- The oncologist
Mucinous histology and resistance to immune checkpoint blockade in patients with microsatellite instability-high metastatic colorectal cancer.
- 13 Apr 2026
- The oncologist
Incidental discovery of second primary lung tumors in breast cancer patients: an institutional case series.
- 10 Apr 2026
- The oncologist
Time dependent outcomes modeling in a real-world analysis of the molecular tumor board at University Cancer Center Hamburg (2016-2022).
- 10 Apr 2026
- The oncologist
Phase 2 Study of Cabozantinib (XL184) with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas (ETCTN10315).
- 10 Apr 2026
- The oncologist
OncoEducate: A Pilot Study of Generative AI to Enhance Patient-Clinician Communication in Genitourinary Cancer Care.
- 9 Apr 2026
- The oncologist
Impact of geriatric covariates on metronomic cyclophosphamide efficacy and tolerance-the CHEMETROLD study.
- 13 Apr 2026
- The oncologist
Mucinous histology and resistance to immune checkpoint blockade in patients with microsatellite instability-high metastatic colorectal cancer.
- 13 Apr 2026
- The oncologist
Incidental discovery of second primary lung tumors in breast cancer patients: an institutional case series.
- 10 Apr 2026
- The oncologist
Time dependent outcomes modeling in a real-world analysis of the molecular tumor board at University Cancer Center Hamburg (2016-2022).
- 10 Apr 2026
- The oncologist
Phase 2 Study of Cabozantinib (XL184) with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas (ETCTN10315).
- 10 Apr 2026
- The oncologist
OncoEducate: A Pilot Study of Generative AI to Enhance Patient-Clinician Communication in Genitourinary Cancer Care.
- 9 Apr 2026
- The oncologist
FAQs on Oncologist
How long has Oncologist been actively publishing? 
What is the publishing frequency of Oncologist?
How many articles did Oncologist publish last year?
What is the eISSN & pISSN for Oncologist?
What is Citescore for Oncologist?
What is SNIP score for Oncologist?
Who is the publisher of Oncologist?
